Real-World Data Study Shows Biosimilar Rituximab for Rheumatoid Arthritis Safe and Effective

A new real-world data (RWD) study published in Rheumatology International found that patients with rheumatoid arthritis who switched from Roche’s biosimilar rituximab to Sandoz’s version of the biosimilar did not suffer any deterioration. Patients who had not taken any version of rituximab also saw similar benefits.

According to Ashley Gallagher, “The treatment effect for individuals who switched was maintained during the follow-up for all disease activity except patient-reported outcomes (PROs). Clinical disease activity index (CDAI) and patient global assessment (PGA) increased after 2 years and were higher than the baseline value from 2.65 to 3.80 and 20 to 30, respectively.”

To read more, click here.

(Source: Pharmacy Times, April 10^th, 2023)